Alogliptin and Somatrogon-Ghla: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Alogliptin
Somatrogon-Ghla
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Reduced insulin sensitivity
Interaction Deep Dive
Adjust the doses of antidiabetic agents when somatrogon-ghla is initiated. Treatment with somatrogon-ghla (a growth hormone) may decrease insulin sensitivity, particularly at higher doses. Monitor glucose levels periodically in all patients receiving somatrogon-ghla, especially in those with risk factors for diabetes mellitus, such as obesity, Turner syndrome, or a family history of diabetes mellitus. New onset type 2 diabetes mellitus has been reported in patients receiving growth hormone1.
Why it happens (mechanism)
Unknown
Literature reports
1 report — tap to read
a) New onset type 2 diabetes mellitus has been reported in patients receiving growth hormone 1.
Common questions
Can I take Alogliptin and Somatrogon-Ghla together?
Reduced insulin sensitivity Always confirm with your pharmacist or prescriber before making any change.
How serious is the Alogliptin and Somatrogon-Ghla interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Alogliptin or Somatrogon-Ghla need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: NGENLA subcutaneous solution, somatrogon-ghla subcutaneous solution. Pfizer Labs (per FDA), New York, NY, 2023. DailyMed
Keep reading about Alogliptin
Keep reading about Somatrogon-Ghla
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist